Pfizer Global Medical Grants (GMG) – 2022/2023 Global COVID-19 ASPIRE – RFP

Well-being, Health and Biomedical Discovery


Academic Unit: Inquire within unit

Memorial Deadline: Thursday 10th, November 2022

External Deadline: Thursday 17th, November 2022


Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an external review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.


Date RFP Issued: October 20, 2022

Geographic Scope: Global

Clinical Area: Anti-Infectives – COVID-19

Link to full RFP: 2022/2023 Global COVID-19 ASPIRE

Letter of Intent (LOI) Due Date: November 17, 2022

Specific Area of Interest: The following areas of research will be considered in-scope:

  • – Societal impact of COVID-19
  • – Key populations at high-risk of severe COVID-19 outcomes
  • – Long term outcomes of COVID-19
  • – Treatment of mild-to-moderate COVID-19 in vaccinated and or seropositive patients with nirmatrelvir/ritonavir
  • – Impact of treatment for mild-to-moderate COVID-19 with nirmatrelvir/ritonavir on viral load, infectivity and/or transmission and/or viral rebound and/or symptom resolution

– Regarding use of nirmatrelvir/ritonavir and showing outcomes: prescription behaviors (reason for non-prescription), patient refusal reasons, access and adherence to treatment

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: January 17, 2023